Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 03, 2015 4:46 PM ET

Capital Markets

Company Overview of BB Biotech AG

Company Overview

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domiciled in Switzerland.

Seestrasse 16

Kusnacht,  CH-8700


Founded in 1993

Key Executives for BB Biotech AG

Head of Biotech, Portfolio Manager, and Member of Executive Board
Age: 45
Chief Financial Officer
Member of Management Team
Member of Management Team
Analyst and Portfolio Manager Biotech
Compensation as of Fiscal Year 2015.

BB Biotech AG Key Developments

BB Biotech AG(DB:BBZA) dropped from Germany TECDAX (Total Return) Index

BB Biotech AG will be removed from Germany TECDAX (Total Return) Index.

BB Biotech AG(DB:BBZA) dropped from Germany TECDAX Index (Price Return)

BB Biotech AG will be removed from Germany TECDAX (Price Return) Index.

BB Biotech Reports Earnings Results for the First Quarter of 2015

BB Biotech reported earnings results for the first quarter of 2015. For the quarter, the company announced that its net profit soared to CHF 379.4 million, boosted by pipeline progress and M&A activity involving its portfolio companies. Net profit in the prior-year period stood at CHF 65.7 million. Net asset value grew by 10.6% in CHF, 27.5% in EUR and 13% in USD over the reporting period. The major growth drivers in the period were mid-cap firms Pharmacyclics, Incyte and Neurocrine, while larger cap holdings did not keep up with benchmark performance, with the exception of Novo Nordisk.

Similar Private Companies By Industry

Company Name Region
NBK Banque Privee (Suisse) S.A. Europe
VantagePoint Global Europe
Research, Consulting & Forecasting SA Europe
Swiss Finance Company Europe
Advisory & Merchant Partners AG Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BB Biotech AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at